Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Myeloma is one of the interleukin (IL)‐6‐related diseases to which abnormal expression of IL‐6 has been reported to be linked. We examined the in vivo inhibitory effect of anti‐human IL‐6 receptor (IL‐6R) antibody on human myeloma cell growth in mice. SCID mice were subcutaneously inoculated with solid tumor of the myeloma cell line S6B45 in which human IL‐6 was acting as an autocrine growth factor. Ten intraperitoneal administrations of 100 μg of the anti‐human IL‐6R antibody PM1 at 48‐h intervals strongly inhibited the growth of S6B45 cells when the administration started 24 h after tumor inoculation. The tumor growth inhibition in vivo was also observed by administration of the anti‐human IL‐6 antibody MH166 using the same procedure as for PM1. The inhibitory effect of PM1 was not significant when the administration started 5 or more days after tumor inoculation. This work indicates that anti‐human IL‐6R antibody, as well as anti‐human IL‐6 antibody inhibits human myeloma growth in vivo, and provides an animal model for testing the therapeutic value of agents such as antibodies to human IL‐6, IL‐6R and gp130, an IL‐6R‐associated signal transducer, in the treatment of human myelomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid colorimetric assay for cell growth and survival
Denizot, F., & Lang, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90368-6 · Cited by 4,935
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationInterleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Self-citationExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Self-citationHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Self-citation
Cited by
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Interleukin-6 (IL-6)—A molecule with both beneficial and destructive potentials
Gadient, R. A., & Otten, U. H. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00021-x · Cited by 481
Tsujinaka, T., Fujita, J., Ebisui, C., Yano, M., Kominami, E., Suzuki, K., Tanaka, K., Katsume, A., Ohsugi, Y., Shiozaki, H., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118398 · Cited by 421
Self-citationMihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328
Self-citationYaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy
Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01519898 · Cited by 52
Hilbert, D. M., Migone, T.-S., Kopf, M., Leonard, W. J., & Rudikoff, S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80312-x · Cited by 40
Metadata
- Authors
- Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T., & Kishimoto, T.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1992-08
- Volume
- 22
- Issue
- 8
- Pages
- 1989-1993
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2097593324
- Cited by
- 93
- References
- 5
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.